Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 In Patients With Ischemic Cardiomyopathy and Angina.

Trial Profile

Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 In Patients With Ischemic Cardiomyopathy and Angina.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2010

At a glance

  • Drugs Omecamtiv mecarbil; Omecamtiv mecarbil
  • Indications Angina pectoris; Cardiomyopathies; Heart failure
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 15 Sep 2009 Results were presented at the 2009 Heart Failure Society of America Annual Meeting in Boston, Massachusetts, according to a Cytokinetics media release.
    • 31 Aug 2009 Results presented at ESC Congress 2009: Annual Congress of the European Society of Cardiology.
    • 31 Aug 2009 Results were presented at the European Society of Cardiology Congress 2009, according to a Cytokinetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top